Rivoceranib is a selective potent inhibitor of vascular endothelial growth factor receptor-2 (known as VEGFR2) which mediates the primary pathway for tumor- mediated angiogenesis. Rivoceranib is a low-molecular inhibitor that is highly regarded as the best-in- class drug due to its high VEGRF-2 selectivity and fewer side effects.
- Development of Paclitaxel Micellar, a Cremophor-free formulation of paclitaxel, is underway for the ovarian cancer treatment. - Increased convenience without prior treatment by applying patent-applied Micelle coating. - An optimal mixture of Paclitaxel based on the form of additives developed to reduce side effects. * It received a marketing authorization by the European Medicines Agency (EMA) under the name of medical product Apealea® (paclitaxel micellar) in 2018, and is currently being commercialized in Europe and in the Middle East and North Africa (MENA) region.
2825 E Cottonwood Pkwy Suite 180,Salt Lake City, UT 84121 U.S.A.Tel
400 Oyster Point Blvd, Suite 214, South San Francisco, CA 94080 U.S.A.